articleThe LancetJul 1, 2020GREEN OA

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Oregon Health & Science University · Sinclair Dermatology · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

480
total citations
FWCI
42.93
Percentile
100%
References
29
Citations per year

Authors

17

Topics & keywords

Keywords
  • Eczema Area and Severity Index
  • Medicine
  • Atopic dermatitis
  • Placebo
  • Adverse effect
  • Randomized controlled trial
  • Internal medicine
  • Clinical trial
No related works found for this paper.

Funding